Arterial thromboembolic events Post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in arterial thromboembolic events Up to 5 to 7 weeks post‐operatively compared with inactive control (low certainty).
3 findings from 1 review
RR 0.67 [0.28, 1.62]
2 studies · 282 participants
Low
RR 3 [0.14, 66.53]
1 study · 22 participants
Low
RR 0.2 [0.01, 3.97]
1 study · 50 participants
Very low
Venous thromboembolic events · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in venous thromboembolic events ‐ Up to 5 to 7 weeks post‐operatively compared with inactive control (low certainty).
2 findings from 1 review
Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in venous thromboembolic events Up to 30 days post‐operatively compared with inactive control (low certainty).
1 finding from 1 review
Failure of PDA closure after first course of treatment (assessed by post‐treatment ECHO) · preterm infants with PDA
Prophylactic administration of paracetamol may leads to lower failure of PDA closure after first course (assessed by… compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay · preterm infants with PDA
Prophylactic administration of paracetamol showed no clear difference in all‐cause mortality during initial hospital stay (by clinical… compared with placebo or no intervention (low certainty).
1 finding from 1 review
Necrotizing enterocolitis during initial hospital stay (by radiological diagnosis) · preterm infants with PDA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Amount of analgesia · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on amount of analgesia. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Patient quality of life · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on patient quality of life. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Viral isolates (HSV isolates identified, with or without clinical symptoms) · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower viral isolates (HSV isolates identified, with or without clinical… compared with placebo; GRADE not reported.
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower presence/absence of HSV oral lesions compared with placebo; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Recurrence of lesions · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Change in cardiac function: number of patients with EF < 45% · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
It is very uncertain whether prophylactic perindopril (2 mg to 4 mg daily) changes change in cardiac function: number of patients with EF < 45% compared with placebo (very low certainty).
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvements in quality of life measures · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
Prophylactic perindopril (2 mg to 4 mg daily) showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Arterial thrombotic events ‐ up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Prophylactic trials: intervention showed no clear difference in arterial thrombotic events Up to 30 days post‐operatively compared with inactive control (low certainty).
2 findings from 1 review
Venous thrombotic events Up to 4 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events at 1 to 2 years · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review